Germany's IQWiG verdict for Sovaldi sets scene for tough pricing negotiations
This article was originally published in Scrip
Executive Summary
Gilead's Sovaldi (sofosbuvir) provides additional benefit in hepatitis C virus (HCV) patients, but that benefit is unquantifiable, according to Germany's health technology appraisal body, IQWiG. The institute's lukewarm evaluation sets the scene for difficult pricing negotiations for Gilead.